Records containing: Schizotypal Personality Disorder

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2023-07-06
A Confirmatory Randomized Controlled Trial Comparing Evolutionary Systems Therapy for Schizotypal Personality Disorder With Cognitive Behavioral Therapy
CLINICAL_TRIALS study record update · 2022-10-10
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
CLINICAL_TRIALS study record update · 2022-06-21
Compassion and Metacognition Based Therapy for Schizotypal Personality Disorder: A Pilot Non-inferiority Randomized Controlled Trial on Repeated Measures.
CLINICAL_TRIALS study record update · 2020-03-10
Psychopathological Differences Between Asperger Syndrome/Normal IQ, no Language Impairment Autism Spectrum Disorder and Schizotypal Disorder in an Adult Sample
CLINICAL_TRIALS study record update · 2018-04-09
A D1 Agonist For Working Memory Enhancement In The Schizophrenia Spectrum
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2017-08-11
ClinicalTrials.gov study NCT02535156
CLINICAL_TRIALS study record update · 2017-02-28
Guanfacine Enhancement of Working Memory: Prospects for Augmenting Cognitive Remediation in the Schizophrenia Spectrum
CLINICAL_TRIALS study record update · 2017-02-10
Pharmacology of Cognition in Schizotypal Personality Disorder: Guanfacine for Cognitive Symptoms in Schizotypal Personality Disorder
CLINICAL_TRIALS study record update · 2016-08-04
Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder
CLINICAL_TRIALS study record update · 2012-07-20
Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder